A Serologic Study of Multiple Sclerosis.

Weil, Arthur; Cleveland, David A.

doi:10.1001/archneurpsyc.1932.02230140129010

Cited by 19 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He immersed spinal cord segments from rats in vitro in the plasma of MS patients and healthy controls for 24 h, observing that blood from MS patients had a demyelinating action. His observations were confirmed by internist Arthur Weil (1887-1969) at Yale University [44]. To further study this apparent demyelinating action, Brickner [45,46 ]and his team conducted several experiments mixing serum from MS patients and controls in vitro with lipoid lecithin and certain esters, while measuring the degree to which the lipoid was broken down by the serum after a 24-hour incubation.…”

Section: Vasodilatory Drug Therapymentioning

confidence: 98%

On the Historical Succession of Vessel-Based Therapies in the Treatment of Multiple Sclerosis

Ganesh

Stahnisch²

2013

Eur Neurol

View full text Add to dashboard Cite

Since 2009, the (CCSVI) model of multiple sclerosis has drawn much attention, and the associated surgical ‘venoplasty' interventions have often been advertised as a novel idea. In fact, it is a new incarnation of various vessel-based therapies attempted for multiple sclerosis in the past, dating back to the 1930s, when Tracy Jackson Putnam (1894-1975) attempted pharmacological anticoagulation. This was followed in the 1940s by Richard M. Brickner's (1896-1959) studies of vasodilatory drugs, which further inspired trials of sympathectomy and ganglionectomy. In the 1950s, Ilya Mark Scheinker (1902-1954) studied vasopressor therapy, while Roy Laver Swank (1909-2008) investigated the effects of a low saturated fat diet in his patients. This paper discusses the longer history of these therapeutic endeavours and the aetiological theories that inspired them.

show abstract